

Supplemental Materials of 3Q FY9/20 Consolidated Financial Results

Aug 6, 2020

Fuji Pharma Co., Ltd.

TSE1

4554




FujiPharma

Sales by Therapeutic Category

(¥million)	FY9/19 1-3Q	FY9/20 1-3Q	YoY Change	
			Amount	Ratio
Hormone drugs	7,869	7,461	▲ 408	-5.2%
Diagnostic drugs	8,445	6,360	▲ 2,085	-24.7%
Metabolic drugs	2,239	2,378	139	6.2%
Nervous system & sensory organs drugs	797	905	108	13.6%
Cellular function affecting drugs	692	726	34	4.9%
Antibiotics & Chemotherapeutics	624	558	▲ 66	-10.6%
Circulatory drugs	709	518	▲ 191	-26.9%
In vitro Diagnostics	509	401	▲ 108	-21.2%
Others	3,549	3,691	142	4.0%
CMO Business (OLIC)	1,887	1,896	9	0.5%
Total	27,324	24,899	▲ 2,425	-8.9%

※CMO Business (OLIC) is the amount after consolidation adjustment

Sales Breakdown by Therapeutic Category



Sales of Major Products

Product Name (¥million)	Therapeutic Category	FY9/19 1-3Q	FY9/20 1-3Q	YoY Change		FY9/20	
				Amount	Ratio	Budget	Progress Ratio
OYPALOMIN [®] Injection	Diagnostic drugs	5,392	4,759	▲ 633	-11.7%	6,849	69.5%
Filgrastim BS Injection Syringe	Metabolic drugs	<u>1,395</u>	1,681	286	20.5%	<u>1,805</u>	93.1%
IOPAQUE [®] Injection	Diagnostic drugs	1,703	1,602	▲ 101	-5.9%	2,444	65.5%
DIENOGEST [®] Tablets	Hormone drugs	832	932	100	12.0%	1,121	83.1%
GABAPEN [®] Tablets	<u>Nervous system & sensory organs drugs</u>	-	834	-	-	<u>988</u>	84.4%
LUNABELL [®] Tablets (LD/ULD)	Hormone drugs	<u>1,279</u>	770	▲ 509	-39.8%	<u>933</u>	82.5%
Favoir [®] Tablets	Hormone drugs	515	713	198	38.4%	766	93.1%
DEXART [®] Injection	Hormone drugs	662	647	▲ 15	-2.3%	875	73.9%
Labellefile [®] Tablets	Hormone drugs	490	617	127	25.9%	769	80.2%
HMG Intramuscular Injection	Hormone drugs	608	546	▲ 62	-10.2%	703	77.7%
UTROGESTAN [®] Vaginal Capsules	Hormone drugs	<u>511</u>	476	▲ 35	-6.8%	<u>803</u>	59.3%
LEVONORGESTREL Tablets	Hormone drugs	214	463	249	116.4%	834	55.5%
FOLYRMON [®] -P Injection	Hormone drugs	476	413	▲ 63	-13.2%	607	68.0%
LIMAPTROST ALFADEX tablets	Metabolic drugs	452	375	▲ 77	-17.0%	559	67.1%
Clomid [®]	Hormone drugs	<u>334</u>	298	▲ 36	-10.8%	<u>456</u>	65.4%
Total Top 15 Sales		14,869	15,133	264	1.8%	20,518	73.8%
Pct. Of Total Sales		54.4%	60.8%			60.7%	
Other Products		10,566	7,869	▲ 2,697	-25.5%	11,193	70.3%
CMO Business (OLIC)		1,887	1,896	9	0.5%	2,118	89.5%
Total		27,324	24,899	▲ 2,425	-8.9%	33,830	73.6%

Acute Medical Care Women's Healthcare

* Underlined products are the Fuji Pharma branded drugs, (branded drugs·branded generic drugs (transferred products) and biosimilars)

* CMO Business (OLIC) is the amount after consolidation adjustment

Note on forecast and prospects

The financial forecasts and other projections provided in this presentation are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks.

Actual results may differ significantly from these forecasts for a number of reasons.

It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification.

Information in this presentation about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

Contact Information

Fuji Pharma Co., Ltd.
Corporate Planning Department

E - Mail : fsk_ir@fujipharma.jp

U R L : <https://www.fujipharma.jp/>

